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1.  INTRODUCTION:  
There is highly prevalence of insulin resistance with 
hypertension, which is a major risk factor to develop type 
2 diabetes mellitus1. Because hypertension and diabetes 
mellitus act as two big risk factors for cardiovascular 
disease, the risk gives a boost to increase when both 
synchronizes generally as part of metabolic syndrome. 
Data from trials of antihypertensive therapy commend that 
the risk of death, heart disease or stroke is around doubled 
in hypertensive diabetic patients with compared to those 
without hypertension 2. 
Most of the classes of antihypertensive drugs contrast with 
respect to their metabolic effects. For example, non-
selective or β1- selective β-blockers drift to reduce insulin 
sensitivity, while angiotensin receptor-1blockers (ARBs)  
are tend to have beneficial effects on glycemic control. β-
blockers have been revealed to potential appearance of 
new-onset type-2 DM in patients with hypertension3. 
Cessation of rennin angiotensin system, on other way , 
have been found to provide metabolic benefits by 
decreasing oxidative stress and recovering nitric oxide 
production, which may improve insulin sensitivity in 
patient with hypertension 4. 
It has been found in many trials that the incidence of new 
onset diabetes is incomparably deflate in patients treated 
with ARBs, ACE inhibitors 5. 
In Indian population, there is no widely known studies on 
correlation between beta blockers and ARBs on blood 
glucose level. Therefore, the present study was planned to 
study the comparative effect of beta blockers and ARBs on 
blood glucose level among Indian population in South 
Delhi hospital. 
2. STUDY DESIGN AND METHODOLOGY 
2.1 The study was carried out in the OPD of Majeedia 
hospital, a 350 bed teaching hospital of Hamdard 
University, New Delhi. The protocol was approved by 
Jamia Hamdard Institutional Review Board (JHIRB) vide 
Approval Letter No. 02/10 dated 29 January 2010. It was a 
prospective study of beta-blockers and ARBs on blood 
glucose level in patients of hypertension without diabetes. 
All patients with established hypertension and those who 
were taking beta blocker and ARBs attending the Majeedia 
hospital were included in the study during the time period 
of February 2010 to June 2010. 
2.2  Study population and assessed parameters: Study was 
carried out in 85 hypertensive patients    without diabetes 
visiting to OPD in the department of medicine. The 
assessed parameters of study was; gender distribution, age 
distribution of subjects and blood glucose levels following 
chronic antihypertensive therapy. 
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2.3 Inclusion and Exclusion Criteria: All patients 
with hypertension without diabetes, receiving 
antihypertensive therapy visiting the OPD of Medicine 
department, Majeedia Hospital were included in the study. 
Patients who were not treated with antihypertensive 
agents. Mentally challenged and unconscious, drug 
addicts, and those who unable to comply were 
contemplated as exclusion criteria. 
2.4 Source of data: Physician’s prescribing records, 
Patients’ medication profile, and Pathology laboratory test 
reports. Patient’s demographics (age, gender, weight, 
blood pressure levels, drug history, glucose levels, etc). 
Patients were interviewed after obtaining informed 
consent. Patients study proforma showing patient’s 
demographics, drug history and pathology test reports. 
2.5   Sample Collection: Blood samples of hypertensive 
patients for oral glucose tolerance test were collected by 
laboratory technician.  The collected samples were sent to 
the in-house pathology lab and the reports were collected 
and interpreted by the investigators/clinician According to 
WHO 1999, fasting blood glucose level between 110 to 
125 mg/dl and 2 hr blood glucose level, after giving 75 gm 
glucose through oral route in between 140-200 mg/dl were 
considered as impaired glucose tolerance. The patients 
were aforethought diabetic when the fasting blood glucose 
level was found to be more than 125 mg/dl and 2 hr post 
prandial blood glucose was more than 200 mg/dl. 
2.6 Ethical Considerations:  the study was based on the 
basic principles defined in US 21 CFR part 312.20 and 
ICH (09 May 1997) ‘Guidance for Good Clinical Practice’ 
and the principles enunciated in the Declaration of 
Helsinki (Edinburgh, October2000). The Protocol and the 
corresponding Informed Consent Form (ICF) were 
submitted to the Jamia Hamdard Institutional Review 
Board (IRB) for the approval of conduct of this study. 
3. OBSERVATION AND RESULT 
3.1 Gender assessment of subjects: 85 Patients were 
assessed to receive antihypertensive therapy during four 
month of study at Majeedia Hospital. Out of 85  patients  
53 %  were male and 47% were female (Table 1). 
Table 1: Gender distribution of subjects: 
Gender No. of Patients 
Percentage of 
Patients 
Male 45 53 
Female 40 47 
Total 85 100 
 
3.2 Age dissemination of subjects: Hypertension was 
found more prevalent in patients of age group between 51-
60 years (40 %) followed by age group 41-50 (21%) years. 
So prevalence of hypertension was more found between 
40-60 years (Table 2). 
 
Table 2: Age distribution of subjects: 
Age (yrs) Male % of male Female % of female Total Total % 
20-30 2 4.4 1 2.5 3 3.5 
31-40 3 6.7 3 7.5 6 7 
41-50 9 20 9 22.5 18 21 
51-60 18 40 16 40 34 40 
61-70 8 17.8 8 20 16 18 
71-80 5 11.1 3 7.5 8 9.5 
Total 45 100 40 100 85 100 
 
Table 3: Blood glucose levels of patients receiving antihypertensive therapy. 
 
Category of  
drug 
First month Second  month Third  month Fourth  month 
FBG PP FBG PP FBG PP FBG PP 
 
Beta-
blockers 
93.12 
±1.62  
122.7    
± 1.28  
97.34 
±4.15 
126.1±5.35 111.1±8.11* 137.45± 
13.01* 
117.37± 
6.8** 
147.25± 
12.43** 
 
ARBs 92.5±0.81 119.5± 
1.3 
94.3±1 122.5±0.93 93.14±1.1* 121.47±1.22* 96.31 ± 
1.11** 
123 ± 
3.4** 
Values were represented as mean ± SEM. 
FBG = Fasting blood glucose level; PP=Blood glucose level after two hours glucose. The data were significant by One way ANOVA followedby  
Tukey’s Multiple Comparison Test. 
P< 0.05, statistically  significant in case of Beta blockers vs ARBs. 
* p < 0.05, ** p < 0.01, ***  if p < 0.0001, 
 
3.3 Out of 85 hypertensive patients, 45 were prescribed 
beta blockers. Among beta blockers, atenolol was the 
most widely prescribed drug followed by metoporolol and 
carvedilol respectively. 40 patients were prescribed 
ARBs. Telmisartan is the most widely prescribed drug 
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followed by Losartan Angiotensin receptor blockers 
(ARB).  
3.4 Blood glucose levels of patients receiving beta 
blockers and ARBs: 
Blood glucose level of patients taking beta blockers and 
ARB as antihypertensive therapy was observed during 
each month. It was found that beta blockers produce 
impairment in postprandial glycemic control in time 
dependent manner. It was found that disturbance in blood 
glucose level increase on prolong therapy of beta 
blockers. There was no any disturbance of blood glucose 
level was found as in case of ARB therapy. It was 
observed that beta blockers cause significant disturbance 
on blood glucose level as compare with ARBs (Table 3). 
3.5 Total incidence of impaired glucose tolerance (IGT) 
or diabetes mellitus (DM)  
During four month of study it was found that 13.3% 
incidence of impaired glucose tolerance and 5 % 
incidence of diabetes mellitus was found in the group of 
patients who were using beta blockers as antihypertensive 
therapy. There was no any case of impaired glucose 
tolerance and Diabetes was found in group of patients 
who were using ARB as antihypertensive therapy (Table 
4).
 
Table 4: Total incidence of IGT and DM in hypertensive patients 
Drugs used as 
antihypertensive therapy 
Number of 
patients 
Incidence 
of DM 
% of Incidence 
of DM 
Incidence of  
IGT 
 
% of 
Incidence of IGT 
Beta blockers 45 2 5% 6 13.3 
ARBs 40 0 0% 0 0 
 
4. DISCUSSION  
Hypertension and diabetes are one of the most prevalent 
disease in worldwide. Diabetes mellitus and drug induced 
hyperglycemia is big issue in aspect of studies indicating 
that the therapy with different antihypertensive drug may 
have variant effect on blood glucose levels. It was believed 
that long term therapy influences these metabolic effects. 
Beta blockers and ARBs are the important drugs used in 
reduction of cardiovascular disease. Beta blockers may 
worsen glucose metabolism which may lead to Diabetes 
mellitus type 2 on long term treatment. ARBs may 
ameliorate insulin sensitivity in hypertensive patients 6. 
Therefore it is big issue to monitor the metabolic 
consequences of antihypertensive drug so that potential 
adverse effect could be minimized. There is no such 
published study available to establish the relationship 
between beta blockers and ARBs on blood glucose level in 
hypertensive patients in Indian population. 
The present study compares the effect of beta blockers and 
ARBs on blood glucose levels of Indian patients receiving 
antihypertensive therapy. The study was carried out in 
University Majeedia hospital at New Delhi. The 
observation was assessed on 85 patients during period of 
four months. 
A higher percentage of male (53) as compared to (47) 
females was found on gender distribution of hypertensive 
patients. Patients who were prescribed beta blockes and 
ARBs In this study hypertensive patients were divided into 
two groups: those who were taking beta blocker and in 
other group who were using ARBs as antihypertensive 
therapy. Higher incidence of impaired glucose tolerance 
(13.3%) and diabetes mellitus (5%) was found in group of 
patients who were taking beta blockers as antihypertensive 
therapy. Thus the high blood glucose levels is a risk factor 
for onset of diabetes mellitus type 2 and it should be 
monitored properly when a patients is prescribing beta 
blockers. 
No any incidence of impaired glucose tolerance or diabetes 
mellitus was observed in group of patients who were 
taking ARBs as antihypertensive therapy.Most of the 
literature supports this observation including the HOPE 
(Heart Outcomes Prevention Evaluation) trial, which 
indicate a reduced rate of new onset of diabetes mellitus in 
patients taking ARBs 7-8. 
Angiotensin receptor blockers may exert wholesome 
effects on glycemic control through a variety of 
mechanisms related to the inhibition of angiotensin II9-10.  
ARBs drug has been reported to activate insulin sensitizing 
peroxisome proliferator-activated receptor, gamma isotype 
pathways so it shows beneficial effect in glycemic control 
11
. 
In conclusion, beta blockers worsen the glycemic 
condition and may increase blood glucose level. It may be 
the risk factor to develop diabetes mellitus type 2 on long 
term use as an antihypertensive therapy. There was no any 
incidence of impaired glucose tolerance or diabetes 
mellitus found in case of patients taking ARBs as an 
antihypertensive therapy so it can be safely prescribe in 
hypertensive patients associated with diabetes mellitus 
type 2. 
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